pI: 7.1112 |
Length (AA): 175 |
MW (Da): 19595 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_129986)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G05080 | ubiquitin-conjugating enzyme E2 22 |
Dictyostelium discoideum | DDB_G0289021 | ubiquitin-conjugating enzyme E2 S |
Drosophila melanogaster | Dmel_CG8188 | CG8188 gene product from transcript CG8188-RD |
Echinococcus granulosus | EgrG_000990700 | ubiquitin conjugating enzyme e2S |
Echinococcus multilocularis | EmuJ_000990700 | ubiquitin conjugating enzyme e2S |
Homo sapiens | 27338 | ubiquitin-conjugating enzyme E2S |
Leishmania braziliensis | LbrM.15.0920 | ubiquitin-conjugating enzyme |
Leishmania braziliensis | LbrM.33.3050 | ubiquitin-conjugating enzyme, putative |
Leishmania donovani | LdBPK_332910.1 | ubiquitin-conjugating enzyme, putative |
Leishmania infantum | LinJ.33.2910 | ubiquitin-conjugating enzyme, putative |
Leishmania major | LmjF.33.2770 | ubiquitin-conjugating enzyme, putative |
Leishmania mexicana | LmxM.32.2770 | ubiquitin-conjugating enzyme, putative |
Mus musculus | ENSMUSG00000060860 | ubiquitin-conjugating enzyme E2S |
Oryza sativa | 4341740 | Os06g0660700 |
Schistosoma japonicum | Sjp_0070110 | ko:K10583 ubiquitin-conjugating enzyme E2 S, putative |
Schistosoma mansoni | Smp_180170 | ubiquitin-conjugating enzyme e2S |
Schmidtea mediterranea | mk4.003876.04 | Ubiquitin-conjugating enzyme E2 S |
Schmidtea mediterranea | mk4.002487.04 | Ubiquitin-conjugating enzyme E2 S |
Schmidtea mediterranea | mk4.040052.00 | Ubiquitin-conjugating enzyme E2 S |
Trypanosoma brucei gambiense | Tbg.972.2.2010 | ubiquitin-conjugating enzyme, putative |
Trypanosoma brucei | Tb927.2.3720 | ubiquitin-conjugating enzyme, putative |
Trypanosoma cruzi | TcCLB.511111.50 | ubiquitin-conjugating enzyme, putative |
Trypanosoma cruzi | TcCLB.507715.80 | ubiquitin-conjugating enzyme, putative |
Trichomonas vaginalis | TVAG_062270 | ubiquitin-conjugating enzyme E2, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.2.3720 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.3720 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.3720 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.2.3720 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.